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This issue of Value in Health [1] includes articles
resulting from an open-registration meeting organized
jointly by the Mayo Clinic College of Medicine and the
Food and Drug Administration (FDA) Center for Drug
Evaluation and Research intended to facilitate review
and discussion of the draft guidance document among
diverse stakeholders and FDA representatives. The
meeting, titled “FDA Guidance on Patient-Reported
Outcomes: Discussion, Dissemination, and Operation-
alization,” was held during February 23–25, 2006, in
Chantilly, VA, USA.
From this meeting, the FDA representatives were
clear in that the guidance document was intended to
be just that: guidance on how the FDA currently
evaluates patient-reported outcomes (PROs) used as
efﬁcacy end points in support of labeling claims. The
guidance is neither a statute nor a regulation nor
inﬂexible over time as the science of PROs evolves. It
was intentionally concise without discussion of spe-
ciﬁc methods or identiﬁcation of acceptable PRO
assessments to avoid being prescriptive.
Some participants during the meeting felt that the
draft guidance document “set the bar too high” in
terms of setting unrealistic expectations for PROs (in
other words, the draft guidance document could
hinder the inclusion of PRO end points in labeling
claims because the “required” documentation of PRO
development is just too extensive and/or expensive).
Nevertheless, the FDA representatives again reiterated
that the draft guidance document is not a strict guide-
line, but rather an effort to make clear how the FDA
evaluates PROs in labeling claims. The FDA represen-
tatives took a very practical view in that via open,
early, and continuing communication throughout the
drug development process, drug developers should
expect limited surprises in the FDA’s review of the
PRO end points in the labeling claim. Thus, a mantra
for those intending to include PRO end points in a
labeling claim should be, “Communication, communi-
cation, communication!”
The FDA representatives expressed a view that
other end points will be and are being held to the same
standard. For example, the FDA representatives
expressed a view that items from the Common Termi-
nology Criteria for Adverse Events [2] if used as efﬁ-
cacy end points would be scrutinized to the same
extent as PRO end points. Further, although some
historical clinical end points have known shortcomings
and do not meet the level of validation suggested by
the draft guidance document (e.g., tumor response)
[3], new clinical end points will be held to the same
expectation in terms of validation and interpretation.
For example, in order to validate a new end point in
adjuvant colon cancer clinical trials, Sargent et al. [4]
performed a meta-analysis of patient-level data across
19 trials to compare the traditional end point of
overall survival to the proposed new end point of
disease-free survival. A similar analysis was under-
taken by Ballman et al. [5] to assess the relationship
between a new end point (6-month progression-free
survival) and the traditional end point (12-month
overall survival) in phase II clinical trials in patients
with glioblastoma multiforme.
All in all, the FDA expects good science when it
comes to PROs in labeling claims. The draft guidance
document along with the articles of this issue provides a
big step forward in presentingwhat is “good science” in
PROs in labeling claims.Many of the challenges in PRO
assessment have been identiﬁed and solutions presented
(e.g., see Current Problems in Cancer) [6,7]. While
meeting participants agreed on many issues, they dis-
agreed on several others (e.g., whether anchor-based or
distribution-based methods are better for determining
the clinical signiﬁcance of PRO changes, or whether all
uncorrelated items should be equally weighted within
a subscale). Fortunately, enough widely accepted
methods (many presented in the articles of this issue)
now exist so that PROs can be developed, applied, and
interpreted with regularity and scientiﬁc integrity in
clinical research and practice. With communication
between drug developers and the FDA, PROs will con-
tinue to be successfully included in labeling claims.
For additional review of discussion during the
meeting, see Dueck et al. [8]
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